Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STRO 5.01 +0.46(10.11%)
Will STRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Other News for STRO
Sutro Biopharma announces initiation of REFRalphaME-L1 Phase 2 trial
Sutro Biopharma Announces Initiation of REFR?ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma price target lowered by $3 at Truist, here's why
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma GAAP EPS of -$0.59, revenue of $25.7M